reports
- Geoffroy Michalet
- Julian Dobrovolschi
- Julian Dobrovolschi
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
- Julian Dobrovolschi
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
- Julian Dobrovolschi
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
SZG SALZGITTER AG
RF EURAZEO SA
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
DTE DEUTSCHE TELEKOM AG
01913 PRADA S.P.A.
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
STLA STELLANTIS N.V.
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
CVC CVC CAPITAL PARTNERS PLC
- Julian Dobrovolschi
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
SZG SALZGITTER AG
RF EURAZEO SA
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
DTE DEUTSCHE TELEKOM AG
01913 PRADA S.P.A.
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
STLA STELLANTIS N.V.
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
CVC CVC CAPITAL PARTNERS PLC
Publication annual report 2024, convening notice for the General Meeti...
Publication annual report 2024, convening notice for the General Meeting and proposal new directors Publication annual report 2024, convening notice for the General Meeting and proposal new directors Regulated information 11 April 2025, 8 am CET Kinepolis Group NV presents its integrated annual report 2024, with a comprehensive overview of the Group's strategic, financial, operational and ESG performance for the year 2024. The report is available in English and Dutch and can be accessed . Kinepolis' annual report 2024 is the first report prepared in accordance with the guidelines of th...
Publication rapport annuel 2024, convocation à l'Assemblée générale et...
Publication rapport annuel 2024, convocation à l'Assemblée générale et proposition de nouveaux administrateurs Publication rapport annuel 2024, convocation à l'Assemblée générale et proposition de nouveaux administrateurs Information réglementée 11 avril 2025, 8h00 CET Kinepolis Group SA présente son rapport annuel intégré 2024, avec un aperçu complet des performances stratégiques, financières, opérationnelles et ESG du Groupe pour l'année 2024. Le rapport est disponible en anglais et en néerlandais et peut être consulté Le rapport annuel 2024 de Kinepolis est le premier rapport prépa...
Publicatie jaarverslag 2024, oproeping Algemene Vergadering en voorste...
Publicatie jaarverslag 2024, oproeping Algemene Vergadering en voorstel nieuwe bestuurders Publicatie jaarverslag 2024, oproeping Algemene Vergadering en voorstel nieuwe bestuurders Gereglementeerd bericht 11 april 2025, 8u00 CET Kinepolis Group NV presenteert haar geïntegreerd jaarverslag 2024, met een uitgebreid overzicht van de strategische, financiële, operationele en ESG-prestaties van de Groep over het jaar 2024. Het verslag is beschikbaar in het Engels en Nederlands en kan worden geraadpleegd . Kinepolis’ jaarverslag 2024 is het eerste verslag dat werd opgesteld in overeenstemm...
- ING Helpdesk
Benelux Morning Notes
DEME Group: Does money make life beautiful? Yes! Euronext: March Madness hits Markets. Kinepolis: Cineplex March 2025 box office revenue at 47% of 2019 level, down 50% YoY. Page Group: 1Q25 trading update; FY25 outlook more uncertain. SBM Offshore: Interesting step, but is it necessary? Staffing: French staffing: ongoing weak volumes in February on tough comps. WDP: €107m of new pre-let development projects
- Jacob Mekhael
MaaT Pharma Positive DSMB safety analysis for MaaT033 phase 2 in allo-...
MaaT announced the positive outcome of a key DSMB safety interim analysis for the phase 2b trial (PHOEBUS), which compares the efficacy and safety of MaaT033 (microbiome therapy, oral capsule) to placebo in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT). We are encouraged by the DSMB outcome, particularly in the context that allo-HSCT is a high risk patient population, and see this as supportive of MaaT033´s good safety profile. We note that MaaT033 is next...
Floridienne S.A.: 4 directors
Four Directors at Floridienne S.A. bought/sold 920 shares at 510.000EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Euronext announces volumes for March 2025
Euronext announces volumes for March 2025 Euronext announces volumes for March 2025 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 7 April 2025 – Euronext, the leading European capital market infrastructure, today announced trading volumes for March 2025. Monthly and historical volume tables are available at this address: CONTACTS ANALYSTS & INVESTORS – Investor Relations Aurélie Cohen Judith Stein 97 MEDIA – Europe Aurélie Cohen 45 Andrea Monzani 13 Belgium ...
Euronext N.V.: 1 director
A director at Euronext N.V. sold 3,000 shares at 132.630EUR and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- ING Helpdesk
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update April 2025: Removing Gimv – Adding Adyen
In this April 2025 update of the KBC Securities' Dynamic Top Pick List, we are removing Gimv and adding Adyen. Since adding Gimv to the Dynamic Top Pick List in mid-December 2024, Gimv's performance has remained flat. However, month-to-date, it has increased by nearly 7%, while the indices have all declined. Given the backdrop of a tariff war brewing, we think it's time to remove Gimv from the Dynamic Top Pick List as medium-sized businesses are more likely to feel the pinch of lower demand and...
Convening of the Annual General Meeting of Euronext N.V.
Convening of the Annual General Meeting of Euronext N.V. Convening of the Annual General Meeting of Euronext N.V. Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 2 April 2025 – Euronext today announced that the Annual General Meeting (“AGM”) will take place on Thursday 15 May 2025 at 10.30 CEST at Beursplein 5, 1012 JW Amsterdam, The Netherlands. The agenda for the meeting is as follows: 1. Opening 2. Presentation by the Chief Executive Officer (discussion item)3. Annual Report 2024a) Explanation of the policy on additions to reserves and dividends (discussion item)b...
Euronext publishes its detailed dividend payment schedule for 2025
Euronext publishes its detailed dividend payment schedule for 2025 Euronext publishes its detailed dividend payment schedule for 2025 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 2 April 2025 – In line with the dividend distribution policy of Euronext, it is proposed to distribute 50% of 2024 reported net profit. As a consequence and subject to approval of shareholders at the Company’s Annual General Meeting to be held on 15 May 2025, the annual gross dividend on the 2024 results to be paid in 2025 amounts to €292.8 million, corresponding to a dividend per share of...
- Jacob Mekhael
MaaT Pharma To present preclinical data on MaaT034 at AACR
MaaT will present new non-clinical data on MaaT034 (donor independent microbiome therapy) at the American Association for Cancer Research (AACR) conference, taking place on 25-30 April. The results demonstrate MaaT034's potential as a combination therapy to improve responses to checkpoint inhibitors in solid tumours. Being co-cultured means MaaT034 is donor-independent, which offers the scale required for the larger solid tumour market. Initial data from the phase 2 placebo-controlled trial of l...
- Guy Sips
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical 2024 was a transformational year, 2025 to scale commerc...
Onward reported its FY24 business update, which underlined a lot of progress yet no major new surprises, and it reaffirms its outlook of main catalysts. Mgmt. confirmed demand is strong, but no commercial outlook was given yet. We look forward to an FDA label expansion for home use in 2025, while we also expect the pivotal Empower BP trial in blood pressure control to kick off. FY24 topline (€ 1.7m) and net result (€ -35.7m) came in line with our expectations, and with a € 60m cash position we b...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.